Spruce Biosciences Inc (NAS:SPRB)
$ 0.4054 0.0099 (2.5%) Market Cap: 16.34 Mil Enterprise Value: -40.49 Mil PE Ratio: 0 PB Ratio: 0.32 GF Score: 32/100

Spruce Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2022 / 02:00PM GMT
Release Date Price: $1.47 (+9.70%)
Yinglu Zhang
RBC Capital Markets - Analyst

Welcome to the 2022 RBC Global Healthcare Conference. My name is Yinglu Zhang, one of the Biotech Equity Research Analysts at RBC. And we're pleased to have Spruce Biosciences with us today. Joining us is Javier Szwarcberg, CEO of Spruce Biosciences.

Just a reminder that if you have any questions for the team, we'll have a quick Q&A session in the end. And with that, Javier, thank you so much for joining us.

Javier Szwarcberg
Spruce Biosciences, Inc. - CEO

Sure, my pleasure to be here.

Questions & Answers

Yinglu Zhang
RBC Capital Markets - Analyst

Maybe just to get started, could you give us an introduction to the company and its lead asset, tildacerfont?

Javier Szwarcberg
Spruce Biosciences, Inc. - CEO

Sure. So Spruce was initially founded in 2014. We licensed tildacerfont from Eli Lilly with an asset that they had thought to develop for depression and anxiety and was repurposed for CAH. So in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot